**Figure legends for supplementary figures**

**Supplementary figure 1:** Among the studies which screened for latent tuberculosis (TB) in patients with inflammatory bowel disease treated with infliximab or adalimumab, overall prevalence of TB stratified by local TB burden (low, intermediate and high)

Weights are from random effects analysis. Grey squares denote the proportional weight of each study in the meta-analysis. I-V: Inverse variance; D+L: DerSimonian and Laird

**Supplementary figure 2:** Prevalence of tuberculosis (TB) in patients with inflammatory bowel disease treated with infliximab or adalimumab stratified by country

Weights are from random effects analysis. Grey squares denote the proportional weight of each study in the meta-analysis. I-V: Inverse variance; D+L: DerSimonian and Laird

**Supplementary Figure 3:** Funnel plot indicating the presence of publication bias

**Supplementary Figure 4**: Overall prevalence of tuberculosis (TB) in patients with Crohn’s disease treated with infliximab or adalimumab, stratified by local TB burden (low, intermediate and high)

Weights are from random effects analysis. Grey squares denote the proportional weight of each study in the meta-analysis. I-V: Inverse variance; D+L: DerSimonian and Laird

**Supplementary Figure 5**: Overall prevalence of tuberculosis (TB) in patients with ulcerative colitis treated with infliximab or adalimumab, stratified by local TB burden (low, intermediate and high)

Weights are from random effects analysis. Grey squares denote the proportional weight of each study in the meta-analysis. I-V: Inverse variance; D+L: DerSimonian and Laird

**Supplementary Figure 6**: Overall prevalence of tuberculosis (TB) in patients with inflammatory bowel disease treated with infliximab, stratified by local TB burden (low, intermediate and high)

Weights are from random effects analysis. Grey squares denote the proportional weight of each study in the meta-analysis. I-V: Inverse variance; D+L: DerSimonian and Laird

**Supplementary Figure 7**: Overall prevalence of tuberculosis (TB) in patients with inflammatory bowel disease treated with adalimumab, stratified by local TB burden (low, intermediate and high)

Weights are from random effects analysis. Grey squares denote the proportional weight of each study in the meta-analysis. I-V: Inverse variance; D+L: DerSimonian and Laird